Research & Regulatory News

Two Pathways, Two Timescales

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

A generic drug demonstrates bioequivalence. The same active ingredient delivered at the same rate and extent. A biosimilar must demonstrate no clinically meaningful difference from its reference, usually requiring comparative clinical studies. Peptides of 40 residues or fewer take the first route.

Key facts

Generic route
ANDA (bioequivalence)
Biosimilar route
Comparative demonstration of similarity
Deciding factor
The 40-amino-acid threshold
Semaglutide
31 residues (generic route)
Consequence
Faster entry, steeper price falls
Cross-route sameness
Synthetic may reference rDNA-origin

What bioequivalence actually requires

Showing that the proposed product delivers the same active ingredient into the body at the same rate and to the same extent as the reference. It is a pharmacokinetic demonstration, generally achievable without new efficacy trials, because the active ingredient is identical and identity can be established analytically.

Why biosimilars cannot do that

A large protein made in living cells is not identical between manufacturers. Glycosylation patterns and higher-order structure depend on the cell line and process, so no two products are the same molecule in the way two batches of a synthesised peptide are. Similarity therefore has to be demonstrated rather than asserted, which usually means comparative clinical work.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why a peptide escapes that

Because at 40 residues or fewer it can be synthesised chemically and characterised completely, sequence, mass, purity, impurity profile, all measurable. Where two products can be shown to be the same molecule by analysis, the reason for demanding comparative clinical evidence falls away.

The cross-route provision

The FDA accepts that an applicant may demonstrate a proposed synthetic peptide is the same as the active ingredient in a previously approved peptide of recombinant DNA origin. So a generic made by chemical synthesis can reference an innovator made in cells. Sameness attaches to the molecule, not to the process, which is a substantive regulatory position rather than a technicality.

What that means commercially

Entry measured in months rather than years, and by many manufacturers at once rather than a few. That is the mechanism behind the reported price falls of 70 to 90 per cent in India within weeks of expiry. Biosimilar markets do not behave that way, because the barrier to entry is far higher.

Where the line sits in this catalogue

Semaglutide at 31 residues, tirzepatide and retatrutide at 39, all on the drug side. IGF-1 LR3 at 83 residues would be handled as a biologic, which is consistent with its recombinant production and with the impurity profile discussed elsewhere on this site. None of this applies to research material, which holds no authorisation and no classification.

Quick reference

Generic drugBiosimilar
Must showBioequivalenceNo clinically meaningful difference
Clinical studiesUsually not requiredUsually required
Applies to≤40 residues>40 residues
Typical entryMonths, many entrantsYears, few entrants

Frequently asked questions

What is the difference between a generic and a biosimilar?

A generic shows bioequivalence. The same active ingredient delivered the same way. A biosimilar shows no clinically meaningful difference, usually requiring comparative clinical studies.

Why can peptides use the generic route?

At 40 residues or fewer they can be synthesised and characterised completely, so sameness can be established analytically.

Can a synthetic generic reference a recombinant product?

Yes. The FDA accepts sameness demonstrated across manufacturing routes, because it attaches to the molecule rather than the process.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.